Functional recovery in parkinsonian monkeys treated with GDNF

Cited by (946)

Items 501–600 of 946

1. Differential effects of the dopamine neurotoxin MPTP in animals with a partial deletion of the GDNF receptor, GFRα1, gene
   Heather A. Boger, Lawrence D. Middaugh, Vandana Zaman, Barry J. Hoffer, Ann‐Charlotte Granholm · 2008 · Brain Research
2. Classic animal models of Parkinson’s disease: a historical perspective
   Adjia Hamadjida, Imane Frouni, Cynthia Kwan, Philippe Huot · 2018 · Behavioural Pharmacology
3. Therapeutic efficacy of glial cell-derived neurotrophic factor loaded collagen scaffolds in ex vivo organotypic brain slice Parkinson’s disease models
   Buket Uçar, Christian Humpel · 2019 · Brain Research Bulletin
4. Glial cell line-derived neurotrophic factor (GDNF) gene and schizophrenia: polymorphism screening and association analysis
   Kyu-Bak Lee, Hiroshi Kunugi, Shinichiro Nanko · 2001 · Psychiatry Research
5. Activation of the extracellular signal‐regulated kinases 1 and 2 by glial cell line‐derived neurotrophic factor and its relation to neuroprotection in a mouse model of Parkinson's disease
   Niklas Lindgren, Rehana K. Leak, Kirsten M. Carlson, Amanda D. Smith, Michael J. Zigmond · 2008 · Journal of Neuroscience Research
6. Dopamine increases glial cell line-derived neurotrophic factor in human fetal astrocytes
   Noa Kinor, Revital Geffen, Eliahu Golomb, Tova Zinman, Gal Yadid · 2001 · Glia
7. Neuroprotection for Parkinson's disease using viral vector-mediated delivery of GDNF
   Jodi L. McBride, Jeffrey H. Kordower · 2002 · Progress in brain research
8. Induction of Neurotrophic and Differentiation Factors in Neural Stem Cells by Valproic Acid
   Walaa Almutawa, Na Hyea Kang, Yi Pan, Lennard P. Niles · 2014 · Basic & Clinical Pharmacology & Toxicology
9. The neurogenic niche in the carotid body and its applicability to antiparkinsonian cell therapy
   José López‐Barneo, Ricardo Pardal, Patricia Ortega‐Sáenz, Rocío Durán, Javier Villadiego, Juan José Toledo‐Aral · 2009 · Journal of Neural Transmission
10. Virally Mediated Overexpression of Glial-Derived Neurotrophic Factor Elicits Age- and Dose-Dependent Neuronal Toxicity and Hearing Loss
    Omar Akil, Bas Blits, Lawrence R. Lustig, Patricia A. Leake · 2018 · Human Gene Therapy
11. GDNF Promotes Survival and Therapeutic Efficacy of Human Adipose-Derived Mesenchymal Stem Cells in a Mouse Model of Parkinson’s Disease
    Shoujia Sun, Quan Zhang, Man Li, Pan Gao, Kuan Huang, Rajluxmee Beejadhursing, Wei Jiang, Ting Lei, Mingxin Zhu, Kai Shu · 2020 · Cell Transplantation
12. Neurotrophic factors in neurodegenerative disorders: Model of parkinson’s disease
    Justo Garcı́a de Yébenes, María A. Mena · 2000 · Neurotoxicity Research
13. Six-Month Continuous Intraputamenal Infusion Toxicity Study of Recombinant Methionyl Human Glial Cell Line-Derived Neurotrophic Factor (r-metHuGDNF) in Rhesus Monkeys
    David N. Hovland, Robert B. Boyd, Mark T. Butt, Jeffery A. Engelhardt, Michael S. Moxness, Mark H. Ma, Maurice G. Emery, Nadia B. Ernst, Randall P. Reed, Jillynne R. Zeller et al. · 2007 · Toxicologic Pathology
14. GDNF Protection against 6-OHDA–Induced Reductions in Potassium-Evoked Overflow of Striatal Dopamine
    Wayne A. Cass, Michael W. Manning · 1999 · Journal of Neuroscience
15. Combining Growth Factors, Stem Cells, and Gene Therapy for the Aging Brain
    Soshana P. Behrstock, Clive Niels Svendsen · 2004 · Annals of the New York Academy of Sciences
16. Glial cell line-derived neurotrophic factor is essential for neuronal survival in the locus coeruleus–hippocampal noradrenergic pathway
    E. Matthew Quintero, Lauren Willis, Vandana Zaman, J Lee, Heather A. Boger, A. Tomac, Barry J. Hoffer, Ingrid Strömberg, A.-Ch. Granholm · 2004 · Neuroscience
17. Surgical therapy for Parkinson's disease
    C. Warren Olanow · 2002 · European Journal of Neurology
18. GDNF treatment in Parkinson's disease: time for controlled clinical trials?
    Patrik Brundin · 2002 · Brain
19. Non-Viral Delivery of the Gene for Glial Cell Line-Derived Neurotrophic Factor to Mesenchymal Stem Cells In Vitro Via a Collagen Scaffold
    Catherine Bolliet, Martha Churchill Bohn, Myron Spector · 2008 · Tissue Engineering Part C Methods
20. GDNF clinical trials for Parkinson’s disease: a critical human dimension
    Don Marshall Gash, Greg A. Gerhardt, Luke H. Bradley, Renee P. Wagner, John T. Slevin · 2020 · Cell and Tissue Research
21. Assessing nigrostriatal dysfunctions by pharmacological MRI in parkinsonian rhesus macaques
    Zhiming Zhang, Anders H. Andersen, Yi Ai, Aaron Loveland, Peter Hardy, Greg A. Gerhardt, Don Marshall Gash · 2006 · NeuroImage
22. Topographical distribution of [125I]-glial cell line-derived neurotrophic factor in unlesioned and MPTP-lesioned rhesus monkey brain following a bolus intraventricular injection
    Paul A. Lapchak, Dalia M. Araujo, Dana C. Hilt, S Jiao, F Collin, Yasuyuki Miyoshi, Yi Ai, Z. Zhang, Don Marshall Gash · 1998 · Brain Research
23. Protective effects of intracerebral adenoviral-mediated GDNF gene transfer in a rat model of Parkinson's disease
    Xianwen Chen, Weiguo Liu, Yang Guoyuan, Zhenguo Liu, Stuart James Smith, Donald B. Calne, Shengdi Chen · 2003 · Parkinsonism & Related Disorders
24. Ape1/Ref-1 Induces Glial Cell-Derived Neurotropic Factor (GDNF) Responsiveness by Upregulating GDNF Receptor α1 Expression
    Mi-Hwa Kim, Hong-Beum Kim, Samudra Acharya, Hong Moon Sohn, Jae Yeoul Jun, In Youb Chang, Ho Jin You · 2009 · Molecular and Cellular Biology
25. Bimodal upregulation of glial cell line‐derived neurotrophic factor (GDNF) in the neonatal rat brain following ischemic/hypoxic injury
    Tomoaki Ikeda, Heasoo Koo, Yi Xin Xia, Tsuyomu Ikenoue, Ben H. Choi · 2002 · International Journal of Developmental Neuroscience
26. Neurotrophic Factors and Neurodegenerative Diseases
    Barbara Ruozi, Daniela Belletti, Lucia Bondioli, Alessandro De Vita, Flavio Forni, Maria Angela Vandelli, Giovanni Tosi · 2012 · International review of neurobiology
27. Topographical localization of glial cell line-derived neurotrophic factor in the human brain stem: an immunohistochemical study of prenatal, neonatal and adult brains
    M. Del Fiacco, Marina Quartu, Maria Pina Serra, Paolo Follesa, Maria Letizia Lai, Alessia Bachis · 2002 · Journal of Chemical Neuroanatomy
28. Control of neuroinflammation as a therapeutic strategy for amyotrophic lateral sclerosis and other neurodegenerative disorders
    Rodney Lee Mosley, Howard Eliot Gendelman · 2010 · Experimental Neurology
29. GDNF signaling in subjects with minimal motor deficits and Parkinson's disease
    Yaping Chu, Jeffrey H. Kordower · 2021 · Neurobiology of Disease
30. Dopaminergic innervation of the rat globus pallidus characterized by microdialysis and immunohistochemistry
    Holger Fuchs, Wolfgang Hauber · 2003 · Experimental Brain Research
31. Decreased expression of ErbB4 and tyrosine hydroxylase mRNA and protein in the ventral midbrain of aged rats
    Jonathan W. Dickerson, Ann M. Hemmerle, Suzanne Numan, Kerstin H. Lundgren, Kim B. Seroogy · 2009 · Neuroscience
32. Assessment of GDNF in Primate Models of Parkinson's Disease: Comparison with Human Studies
    Andisheh Eslamboli · 2005 · Reviews in the Neurosciences
33. Targeting kinases in Parkinson's disease: A mechanism shared by LRRK2, neurotrophins, exenatide, urate, nilotinib and lithium
    Thomas J. Guttuso, Kelly L. Andrzejewski, David Gordon Lichter, Julie Kay Andersen · 2019 · Journal of the Neurological Sciences
34. Dopaminergic cells of the carotid body: physiological significance and possible therapeutic applications in Parkinson’s disease
    Juan José Toledo‐Aral, Simón Méndez‐Ferrer, Ricardo Pardal, José López‐Barneo · 2002 · Brain Research Bulletin
35. Effect of glial cell line‐derived neurotrophic factor (GDNF) co‐transplantation with fetal ventral mesencephalic cells (VMC) on functional restoration in 6‐hydroxydopamine (6‐OHDA) lesioned rat model of Parkinson's disease: neurobehavioral, neurochemical and immunohistochemical studies
    Rajnish Kumar Chaturvedi, A.K. Agrawal, Kavita Seth, S. Shukla, S. Chauhan, Yogeshwar Shukla, Chaitali Sinha, P. K. Seth · 2003 · International Journal of Developmental Neuroscience
36. Absence of the dopamine D2 receptor leads to a decreased expression of GDNF and NT‐4 mRNAs in restricted brain areas
    Yuri Bozzi, Emiliana Borrelli · 1999 · European Journal of Neuroscience
37. Translating the therapeutic potential of neurotrophic factors to clinical ‘proof of concept’: A personal saga achieving a career-long quest
    Raymond T. Bartus · 2012 · Neurobiology of Disease
38. Expression of glial cell line‐derived neurotrophic factor (GDNF) in the developing human fetal brain
    Heasoo Koo, Bernard Choi · 2001 · International Journal of Developmental Neuroscience
39. mGluR2/3 agonist LY379268, by enhancing the production of GDNF, induces a time-related phosphorylation of RET receptor and intracellular signaling Erk1/2 in mouse striatum
    Valentina Di Liberto, Giuseppa Mudò, Natale Belluardo · 2011 · Neuropharmacology
40. Evidence for Sprouting of Dopamine and Serotonin Axons in the Pallidum of Parkinsonian Monkeys
    Dave Gagnon, Lara Eid, Dymka Coudé, Carl Whissel, Thérèse Di Paolo, André Parent, Martin Parent · 2018 · Frontiers in Neuroanatomy
41. Expression and localization of GDNF in developing and adult adrenal chromaffin cells
    Kerstin G. KRIEGLSTEIN, Frauke Deimling, Clemens Suter‐Crazzolara, Klaus Unsicker · 1996 · Cell and Tissue Research
42. Kidney Cografts Enhance Fiber Outgrowth From Ventral Mesencephalic Grafts to the 6-OHDA–Lesioned Striatum, and Improve Behavioral Recovery
    Ann-Charlotte Granholm, Stephanie Henry, Meleik A. Hebert, Servet Eken, Greg A. Gerhardt, Craig G. van Horne · 1998 · Cell Transplantation
43. Transport of Glial Cell Line-Derived Neurotrophic Factor into Liposomes across the Blood-Brain Barrier: In Vitro and in Vivo Studies
    Shao-Ling Wu, Guoqi Li, Xiao Li, Caina Lin, Ding Yu, Shuo Luan, Chao Ma · 2014 · International Journal of Molecular Sciences
44. Failure of Glial Cell-Line Derived Neurotrophic Factor (GDNF) in Clinical Trials Orchestrated By Reduced NR4A2 (NURR1) Transcription Factor in Parkinson’s Disease. A Systematic Review
    Piniel Alphayo Kambey, Kouminin Kanwore, Abiola Abdulrahman Ayanlaja, Iqra Nadeem, Du Yinzhen, Wokuheleza Buberwa, Wenya Liu, Dianshuai Gao · 2021 · Frontiers in Aging Neuroscience
45. Long distance directional growth of dopaminergic axons along pathways of netrin-1 and GDNF
    C. Zhang, Ying Jin, Kristine S. Ziemba, Anita M. Fletcher, Biswarup Ghosh, E. Truit, David M. Yurek, George M. Smith · 2013 · Experimental Neurology
46. Some aspects of astroglial functions and aluminum implications for neurodegeneration
    David A. Aremu, Shunsuke Meshitsuka · 2006 · Brain Research Reviews
47. Pathways towards an effective immunotherapy for Parkinson’s disease
    Jessica A.L. Hutter-Saunders, Rodney Lee Mosley, Howard Eliot Gendelman · 2011 · Expert Review of Neurotherapeutics
48. 2‐DE profiling of GDNF overexpression‐related proteome changes in differentiating ST14A rat progenitor cells
    Raimund Hoffrogge, Susanne Beyer, Rayk Hübner, Stefan Mikkat, Eilhard Mix, Christian Scharf, Ulf Schmitz, Stefan Pauleweit, Matthias Berth, Igor Z. Zubrzycki et al. · 2006 · PROTEOMICS
49. Alzheimer'S Disease: Advances In Genetics, Molecular And Cellular Biology
    Sangram S. Sisodia, Rudolph E. Tanzi · 2007
50. GDNF
    Kevin M. Walton · 1999 · Molecular Neurobiology
51. Cyclosporine A-Induced Hyperactivity in Rats: Is it Mediated by Immunosuppression, Neurotrophism, or Both?
    Cesar V. Borlongan, Christine E. Stahl, Tomoko Fujisaki, Paul R. Sanberg, Shigeru Watanabe · 1999 · Cell Transplantation
52. Prevention of dopaminergic neuron death by adeno-associated virus vector-mediated GDNF gene transfer in rat mesencephalic cells in vitro
    Dongsheng Fan, Matsuo Ogawa, Kunihiko Ikeguchi, Ken-ichi Fujimoto, Masashi Urabe, Akihiro Kume, Masatoyo Nishizawa, Natsuki Matsushita, Kazutoshi Kiuchi, Hiroshi Ichinose et al. · 1998 · Neuroscience Letters
53. Gene therapy: a viable therapeutic strategy for Parkinson’s disease?
    Alexander L. Berry, Thomas Foltynie · 2010 · Journal of Neurology
54. The Role of Group II Metabotropic Glutamate Receptors in the Striatum in Electroacupuncture Treatment of Parkinsonian Rats
    Yanjun Jia, Jiahui Deng, Wen‐Zhong Zhang, Zuoli Sun, Jian Yang, Yan Yu, Xiaoli Gong, Jun Jia, Xiaomin Wang · 2016 · CNS Neuroscience & Therapeutics
55. Distribution and immunohistochemical localization of GDNF protein in selected neural and non-neural tissues of rats during development and changes in unilateral 6-hydroxydopamine lesions
    Ritsuko Katoh‐Semba, Masako Tsuzuki, Noriko Miyazaki, Akiko Yoshida, Hidemitsu Nakajima, Chiaki W. Nakagawa, Satoko Kitajima, Motoko Matsuda · 2007 · Neuroscience Research
56. A 6-Hydroxydopamine In Vivo Model of Parkinson’s Disease
    Giulia Mercanti, Gianfranco Bazzu, Pietro Giusti · 2012 · Methods in molecular biology
57. Gene therapy approaches in the non-human primate model of Parkinson’s disease
    Diego Pignataro, Diego Sucunza, Alberto J. Rico, Iria G. Dopeso‐Reyes, Elvira Roda, Ana Isabel Rodriguez-Perez, José Luis Labandeira-García, Vania Broccoli, Shigeki Kato, Kazuto Kobayashi et al. · 2017 · Journal of Neural Transmission
58. Effects of repeated morphine on locomotion, place preference and dopamine in heterozygous glial cell line‐derived neurotrophic factor knockout mice
    Mikko Airavaara, H. Tuomainen, Petteri T. Piepponen, Märt Saarma, L Ahtee · 2006 · Genes Brain & Behavior
59. Involvement of GDNF in Neuronal Protection against 6-OHDA-Induced Parkinsonism Following Intracerebral Transplantation of Fetal Kidney Tissues in Adult Rats
    Cesar V. Borlongan, Feng C. Zhou, T. HAYASHI, Tsung‐Ping Su, Barry J. Hoffer, Y. Wang · 2001 · Neurobiology of Disease
60. Role of apoptosis in the pathogenesis of Parkinson's disease: A novel therapeutic opportunity?
    Ilan Ziv, Eldad Melamed · 1998 · Movement Disorders
61. Sonic hedgehog delivered by an adeno-associated virus protects dopaminergic neurones against 6-OHDA toxicity in the rat
    B. Dass, Mahmoud M. Iravani, Chi-Shuan Huang, James Barsoum, Thomas M. Engber, Alphonse Galdes, Peter G. Jenner · 2004 · Journal of Neural Transmission
62. Antiparkinsonian Drugs and Their Neuroprotective Effects.
    Yoshihisa Kitamura, Jun‐ichi Kakimura, Takashi Taniguchi · 2002 · Biological and Pharmaceutical Bulletin
63. GDNF Induces Recovery of the Nigrostriatal Dopaminergic System in the Rat Brain Following Intracerebroventricular or Intraparenchymal Administration
    Mizuho Aoi, Isao Date, S. Tomita, T Ohmoto · 2000 · Acta Neurochirurgica
64. The Proform of Glia Cell Line-Derived Neurotrophic Factor: a Potentially Biologically Active Protein
    Xiaolong Sun, Bei‐Yu Chen, Li Na Duan, Yi Xia, Zhuo-Jing Luo, Jingjie Wang, Zhi‐Ren Rao, Liang-Wei Chen · 2013 · Molecular Neurobiology
65. Multi-parameter Behavioral Phenotyping of the MPP+ Model of Parkinson’s Disease in Zebrafish
    Christian Christensen, Haraldur S. Thorsteinsson, Valerie Helene Maier, Karl Æ. Karlsson · 2020 · Frontiers in Behavioral Neuroscience
66. Enhanced dopamine transporter activity in middle-aged Gdnf heterozygous mice
    O. Meagan Littrell, François Pomerleau, Peter F. Huettl, Stewart P. Surgener, Jacqueline F. McGinty, Lawrence D. Middaugh, Ann‐Charlotte Granholm, Greg A. Gerhardt, Heather A. Boger · 2010 · Neurobiology of Aging
67. Sendai Virus Vector-mediated Gene Transfer of Glial Cell Line-Derived Neurotrophic Factor Prevents Delayed Neuronal Death after Transient Global Ischemia in Gerbils.
    Masayuki Shirakura, Masayuki Fukumura, Makoto Inoue, Satoshi FUJIKAWA, Mitsuyo Maeda, Kazuhiko Watabe, Shigeru Kyuwa, Yasuhiro Yoshikawa, Mamoru Hasegawa · 2003 · EXPERIMENTAL ANIMALS
68. Zonisamide reduces nigrostriatal dopaminergic neurodegeneration in a mouse genetic model of Parkinson's disease
    Hiromi Sano, Miho Murata, Atsushi Nambu · 2015 · Journal of Neurochemistry
69. GLIA: A reassessment based on novel data on the developing and mature central nervous system
    Santiago Nahuel Villegas, Fernando Adrian Poletta, Néstor Gabriel Carri · 2003 · Cell Biology International
70. Prospects for the treatment of Parkinson’s disease using neurotrophic factors
    Carrie B. Hurelbrink, Roger A. Barker · 2001 · Expert Opinion on Pharmacotherapy
71. Gene therapy strategies for rare monogenic disorders with nuclear or mitochondrial gene mutations
    Yi Wang, Li‐Fan Hu, Tian‐Jiao Zhou, Lian‐Yu Qi, Lei Xing, Jaiwoo Lee, Fengzhen Wang, Yu‐Kyoung Oh, Hu‐Lin Jiang · 2021 · Biomaterials
72. Prosaptide™ D5, a retro-inverso 11-mer peptidomimetic, rescued dopaminergic neurons in a model of Parkinson’s disease
    Jian Liu, Cui Ying Wang, John S. O’Brien · 2001 · The FASEB Journal
73. Protection of cultured dopamine neurons from MPP + requires a combination of neurotrophic factors
    Juliann D. Jaumotte, Stephanie L. Wyrostek, Michael J. Zigmond · 2016 · European Journal of Neuroscience
74. Neuroprotective Potential of a Small Molecule RET Agonist in Cultured Dopamine Neurons and Hemiparkinsonian Rats
    Juho‐Matti Renko, Arun Kumar Mahato, Tanel Visnapuu, Konsta Valkonen, Mati M. Karelson, Merja H. Voutilainen, Märt Saarma, Raimo K. Tuominen, Yulia A. Sidorova · 2021 · Journal of Parkinson s Disease
75. The Impact of Neurotechnology on Rehabilitation
    Theodore W. Berger, Greg A. Gerhardt, Mark A. Liker, Walid Soussou · 2008 · IEEE Reviews in Biomedical Engineering
76. Chemical conversion of mouse fibroblasts into functional dopaminergic neurons
    Yonghui Wang, Hao Yang, Qiong Yang, Junhua Yang, Hao Wang, Huiming Xu, Wei‐Qiang Gao · 2016 · Experimental Cell Research
77. Invited review: Utilizing peripheral nerve regenerative elements to repair damage in the CNS
    Nader El Seblani, Andrew S. Welleford, Jorge E. Quintero, Craig G. van Horne, Greg A. Gerhardt · 2020 · Journal of Neuroscience Methods
78. Exogenous administration of glial cell line-derived neurotrophic factor improves recovery after spinal cord injury
    Cheng-Hsing Kao, Sheng-Hsien Chen, Chung‐Ching Chio, Chen-Kuei Chang, Mao‐Tsun Lin · 2008 · Resuscitation
79. Quantitative Analysis of Transgene Protein, mRNA, and Vector DNA Following Injection of an Adenoviral Vector Harboring Glial Cell Line-Derived Neurotrophic Factor into the Primate Caudate Nucleus
    Dorothy Annette Kozlowski, Eric Bremer, D. Eugene Redmond, David George, Beth Larson, Martha Churchill Bohn · 2001 · Molecular Therapy
80. Neurotrophins as Therapeutic Agents for Parkinson’s Disease; New Chances From Focused Ultrasound?
    Alessandro Stefani, Mariangela Pierantozzi, Silvia Cardarelli, Lucrezia Stefani, Rocco Cerroni, Matteo Conti, Elena Garasto, Nicola Biagio Mercuri, Carmine Marini, Patrizia Sucapane · 2022 · Frontiers in Neuroscience
81. Adenoviral Vector‐Mediated Delivery Of Glial Cell Line‐Derived Neurotrophic Factor Provides Neuroprotection In The Aged Parkinsonian Rat
    Bronwen J. Connor · 2001 · Clinical and Experimental Pharmacology and Physiology
82. Evaluation and Optimization of the Administration of Recombinant Adeno-Associated Viral Vectors (Serotypes 2/1, 2/2, 2/rh8, 2/9, and 2/rh10) by Convection-Enhanced Delivery to the Striatum
    Edward White, Alison S. Bienemann, Miguel Sena‐Esteves, Hannah Taylor, Chotirote Bunnun, Emma S. Castrique, Steven S. Gill · 2010 · Human Gene Therapy
83. Large Animal Models of Neurological Disorders for Gene Therapy
    Christine Gagliardi, Bruce Alan Bunnell · 2009 · ILAR Journal
84. Constitutive Ret signaling is protective for dopaminergic cell bodies but not for axonal terminals
    Jelena Mijatovic, Marjo Piltonen, Paolo Alberton, Pekka T. Männistö, Märt Saarma, Petteri T. Piepponen · 2009 · Neurobiology of Aging
85. Exercise-Mediated Increase in Nigral Tyrosine Hydroxylase Is Accompanied by Increased Nigral GFR-α1 and EAAC1 Expression in Aging Rats
    Jennifer C. Arnold, Michael F. Salvatore · 2015 · ACS Chemical Neuroscience
86. Role of Glial Cell Line‐Derived Neurotrophic Factor in the Maintenance of Adult Mesencephalic Catecholaminergic Neurons
    Daniel Enterría‐Morales, Ivette López‐López, José López‐Barneo, Xavier d’Anglemont de Tassigny · 2020 · Movement Disorders
87. Characterization of the striatal dopaminergic neurotransmission in MEN2B mice with elevated cerebral tissue dopamine
    Jelena Mijatovic, Outi Patrikainen, Leonid Yavich, Mikko Airavaara, Liisa Ahtee, Märt Saarma, Petteri T. Piepponen · 2008 · Journal of Neurochemistry
88. Co‐transplantation of carotid body and ventral mesencephalic cells as an alternative approach towards functional restoration in 6‐hydroxydopamine‐lesioned rats: implications for Parkinson's disease
    Shubha Shukla, A. K. Agrawal, Rajnish Kumar Chaturvedi, Kavita Seth, N. Srivastava, Chaitali Sinha, Y. Shukla, Vinay Kumar Khanna, P. K. Seth · 2004 · Journal of Neurochemistry
89. Transplantation of Fetal Kidney Cells: Neuroprotection and Neuroregeneration
    Yung Hsiao Chiang, Cesar V. Borlongan, Feng Zhou, Barry J. Hoffer, Yun Wang · 2005 · Cell Transplantation
90. Action of the neurotrophins on calcium uptake
    Hao Jiang, Gordon Guroff · 1997 · Journal of Neuroscience Research
91. Neurotrophic Roles of GDNF and Related Factors
    Klaus Unsicker, Clemens Suter‐Crazzolara, Kerstin G. KRIEGLSTEIN · 1999 · Handbook of experimental pharmacology
92. TAT-PAX6 protein transduction in neural progenitor cells: A novel approach for generation of dopaminergic neurones in vitro
    Katie Spitere, André Toulouse, David B. O’Sullivan, Aideen M. Sullivan · 2008 · Brain Research
93. Implantation of autologous peripheral nerve grafts into the substantia nigra of subjects with idiopathic Parkinson's disease treated with bilateral STN DBS: a report of safety and feasibility
    Craig G. van Horne, Jorge E. Quintero, Julie A. Gurwell, Renee P. Wagner, John T. Slevin, Greg A. Gerhardt · 2016 · Journal of neurosurgery
94. Methodology and effects of repeated intranasal delivery of DNSP-11 in a rat model of Parkinson's disease
    Mallory J. Stenslik, Lisa F. Potts, James Sonne, Wayne A. Cass, Jadwiga T. Turchan-Cholewo, François Pomerleau, Peter F. Huettl, Yi Ai, Don Marshall Gash, Greg A. Gerhardt et al. · 2015 · Journal of Neuroscience Methods
95. Dopamine D1and D2Receptor-Mediated Acute and Long-Lasting Behavioral Effects of Glial Cell Line-Derived Neurotrophic Factor Administered into the Striatum
    Satoshi Kobayashi, Sven Ove Ögren, Barry J. Hoffer, Lars Olson · 1998 · Experimental Neurology
96. Gene therapy of Parkinson’s disease using Adeno-Associated Virus (AAV) vectors
    Katsusuke OZAWA, D S Fan, Yan‐Qin Shen, Shin‐ichi Muramatsu, K. Fujimoto, Kunihiko Ikeguchi, Matsuo Ogawa, Masashi Urabe, Akihiro Kume, Imaharu Nakano · 2000 · Springer eBooks
97. Neuroprotective approaches to halt Parkinson's disease progression
    Piyong Sola, Praveen Thaggikuppe Krishnamurthy, Mamta Kumari, Gowramma Byran, Hosahalli Veerabhadrappa Gangadharappa, Kusuma Kumari Garikapati · 2022 · Neurochemistry International
98. Postnatal Development of Neurons, Interneurons and Glial Cells in the Substantia Nigra of Mice
    Manami Abe, Hiroki Kimoto, Risa Eto, Taeko Sasaki, Hiroyuki Kato, Jiro Kasahara, Tsutomu Araki · 2010 · Cellular and Molecular Neurobiology
99. Recombinant adenoassociated virus 2/5-mediated gene transfer is reduced in the aged rat midbrain
    Nicole K. Polinski, Sara E. Gombash, Fredric P. Manfredsson, Jack W. Lipton, Christopher J. Kemp, Allyson Cole-Strauss, Nicholas M. Kanaan, Kathy Steece‐Collier, Nathan C. Kuhn, Susan L. Wohlgenant et al. · 2014 · Neurobiology of Aging
100. Advances in Neurotrophic Factor and Cell-Based Therapies for Parkinson's Disease: A Mini-Review
     Michael D. Staudt, Andrea R. Di Sebastiano, Hu Xu, Mandar Jog, Susanne Schmid, Paula J. Foster, Matthew O. Hebb · 2015 · Gerontology